Investor Presentation First Nine Months of 2022

26 Investor presentation First nine months of 2022 The acquisition of Dicerna Pharmaceuticals and their RNAi technology in 2021 provided access to intracellular targets Disease targets (expressed genes) • Opportunity to silence genes Cell ~5,000 extracellular targets ~21,000 intracellular targets • Peptides and proteins m XX Genes (DNA) on chromosomes RNAi mRNA Highly specific for targeted gene • Drugability of intracellular targets • Reversible yet long-acting therapies RNA: Ribonucleic acid; mRNA: messenger RNA Engage on the temporary genetic level with RNA therapeutics Novo NordiskⓇ

View entire presentation